Ionis Pharmaceuticals
CompanyUnited StatesFounded 1989
Ionis Pharmaceuticals develops one asset, in phase 1 (ION717 in prion disease). Mostly oligonucleotide acting on PRNP and proteostasis; based in the United States, founded in 1989.
- 1
- Asset
- Furthest
- Phase 1
- 4
- Trials
- 0
- Signals
Pipeline
1Intrathecal antisense oligonucleotide reducing expression of PRNP messenger RNA to prevent prion pathology.
Phase 1, Oligonucleotide, PRNP, Proteostasis, prion disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials6
- Similar companies6
Updated 9 Oct 2026 · 19 sources